Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled nitric oxide after transcatheter mitral valve repair in mitral regurgitation with pulmonary hypertension
jRCTs051230200Recruiting
- Sponsor
- INO Therapeutics
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nitric oxide in mitral regurgitation (MR) and pulmonary hypertension (PH), sponsored by INO Therapeutics. Primary endpoint: Change in pulmonary vascular resistance (PVR) from baseline to 1 day after TMVr. Started Mar 2024; status: recruiting.
02
Drugs
nitric oxide
03
Conditions
mitral regurgitation (MR)pulmonary hypertension (PH)
Beyond the preview
Go deeper on jRCTs051230200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230200.